Lupin
- ISIN
- INE326A01037
- Instrument key
- NSE_EQ|INE326A01037
as of 21/11/2026, 5:08:46 pm
- Open
- ₹1,992.00
- Day high
- ₹2,014.00
- Day low
- ₹1,985.10
- Prev. close
- ₹1,998.80
- Volume
- 6.31 L
- VWAP
- ₹1,995.55
02/Price history
Price chart
1 day · 5-minute candles. Hover the chart for the OHLC of any candle; the table below holds the same data row by row.
No candles for this range
Intraday candles are empty outside market hours — pick a longer range.
Candle data0 rows of open, high, low, close and volumeShowHide
No candles in this range
03/Valuation & returns
Key ratios vs sector
Company value benchmarked against the sector median. The ratio set is sector specific — banks report NIM, CASA and Net NPA instead of EV/EBITDA.
Price ÷ earnings per share
Worse than sector by 139%
Price ÷ book value per share
Better than sector by 9%
Net income ÷ total assets
Better than sector by 999%
Net income ÷ shareholders' equity
Better than sector by 5512%
EBIT ÷ capital employed
Better than sector by 59%
Liquid assets ÷ current liabilities
Worse than sector by 70%
Enterprise value ÷ EBITDA
Better than sector by 55%
04/Business
About the company
Sector: Pharmaceuticals
Lupin Limited is a global pharmaceutical company, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. It operates in India and the United States across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. It has a presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, Gastro-Intestinal, Anti-Infectives and Nonsteroidal Anti-Inflammatory Drug therapy segments and operates in the Anti-TB and Cephalosporins segments. Its generic formulations include Filgrastim, Peg filgrastim, Etanercept and Albuterol. Its diabetes brands include Gibtulio, Ajaduo, Gibtulio Met, ONDERO and ONDERO MET. Its other brands include AntaGolin, RyChol and others. Its Huminsulin range of products includes Insulin Human.
- ₹91,916 Cr
- $10.21B
reported in crore
reported in billion
Market capitalisation is reported at the sector-constituent level, not the standalone company level.
05/Profit & loss
Consolidated income statement
Quarterly figures in ₹ crore. Growth marked reported is provided; margins are derived.
- Revenue · Sep 2026
- ₹7,954 Cr-5.39% vs Jun 2026
- Net profit · Sep 2026
- ₹1,155 Cr-18.47% vs Jun 2026
- Operating margin
- 19.9%was 24.0%
- Revenue CAGR · 4p
- 3.0%profit -0.7% · op 1.2%
| Revenue | 7,954 | 8,407 | 7,615 | 7,282 |
|---|---|---|---|---|
| Revenue growthreported | -5.4% | 10.4% | 4.6% | — |
| Operating profit | 1,580 | 2,017 | 1,928 | 1,522 |
| Operating profit growthreported | -21.7% | 4.6% | 26.7% | — |
| Operating marginderived | 19.9% | 24.0% | 25.3% | 20.9% |
| Net profit | 1,155 | 1,417 | 1,469 | 1,181 |
| Net profit growthreported | -18.5% | -3.5% | 24.4% | — |
| Net marginderived | 14.5% | 16.9% | 19.3% | 16.2% |
| EPS — basic₹/share, annual | — | — | 116.75 | — |
Figures in ₹ crore. Margin rows are computed from the reported values.
Full annual line itemsRevenue, other income, expenses, tax, EPSShowHide
| Revenue | 27,958 | 22,708 | 20,011 | 16,642 |
|---|---|---|---|---|
| Other Income | 1,081 | 202 | 131 | 151 |
| Total Revenue | 29,039 | 22,910 | 20,142 | 16,793 |
| Total Expenses | 21,608 | 18,895 | 17,719 | 16,076 |
| Profit Before Tax | 6,873 | 4,015 | 2,422 | 716 |
| Tax | 1,517 | 709 | 487 | 269 |
| Profit After Tax | 5,355 | 3,306 | 1,936 | 448 |
| EPS - Basic | 116.75 | 71.95 | 42.05 | 9.46 |
| EPS - Diluted | 116.44 | 71.69 | 41.87 | 9.41 |
This breakdown is available annually, even when the summary above is quarterly. EPS rows are per share.
06/Balance sheet
Consolidated balance sheet
Only annual balance sheets are available — the quarterly filter does not apply here. Figures in ₹ crore; net worth is assets minus liabilities.
- Total assets · Mar 2026
- ₹38,365 Cr+31.36% YoY
- Total liabilities
- ₹15,851 Cr
- Net worth
- ₹22,513 Cr
- Liabilities ÷ assets
- 41.3%lower means a lighter balance sheet
| Total assets | 38,365 | 29,205 | 23,997 | 22,956 |
|---|---|---|---|---|
| Total liabilities | 15,851 | 11,911 | 9,624 | 10,413 |
| Net worthderived | 22,513 | 17,294 | 14,373 | 12,543 |
| Liabilities ÷ assetsderived | 41.3% | 40.8% | 40.1% | 45.4% |
| Asset growthderived | 31.4% | 21.7% | 4.5% | — |
Figures in ₹ crore. Stacked chart height equals total assets.
Full annual line itemsNon-current & current assets, liabilities, equity capitalShowHide
| Non-Current Assets | 14,337 | 12,406 | 10,550 | 10,505 |
|---|---|---|---|---|
| Current Assets | 24,027 | 16,799 | 13,448 | 12,451 |
| Total Assets | 38,365 | 29,205 | 23,997 | 22,956 |
| Current Liabilities | 12,651 | 8,961 | 8,502 | 9,265 |
| Net Current Asset | 11,376 | 7,837 | 4,946 | 3,186 |
| Non-Current Liabilities | 3,200 | 2,949 | 1,122 | 1,148 |
| Equity Capital | 22,513 | 17,294 | 14,373 | 12,543 |
| Total Equity & Liabilities | 38,365 | 29,205 | 23,997 | 22,956 |
Figures in ₹ crore unless the line item is per-share.
07/Cash flow
Consolidated cash flow
Annual only, in ₹ crore. Negative values are outflows, so healthy companies usually show positive operating and negative investing cash flow.
- Operating · Mar 2026
- ₹7,335 Cr+144.49% YoY
- Investing
- -₹3,865 Cr
- Financing
- -₹846 Cr
- Free cash flow
- ₹3,470 Croperating + investing
| Operating activities | 7,335 | 3,000 | 3,648 | 1,897 |
|---|---|---|---|---|
| Operating changereported | 144.5% | -17.8% | 92.3% | — |
| Investing activities | -3,865 | -4,172 | -1,712 | -1,287 |
| Investing changereported | 7.4% | -143.7% | -33.1% | — |
| Financing activities | -846 | 1,732 | -2,184 | -337 |
| Financing changereported | -148.8% | 179.3% | -547.6% | — |
| Net cash flowderived | 2,624 | 560 | -248 | 273 |
| Free cash flowoperating + investing | 3,470 | -1,172 | 1,936 | 610 |
Figures in ₹ crore.
Full annual line itemsProfit before tax through closing cash balanceShowHide
| Profit before tax | 6,873 | 4,015 | 2,422 | 716 |
|---|---|---|---|---|
| Income before WC changes | 7,968 | 5,317 | 3,889 | 1,814 |
| Change in Assets | -1,814 | -1,239 | -702 | -112 |
| Change in Liabilities | 2,447 | -172 | 788 | 438 |
| Change in WC | 634 | -1,411 | 86 | 327 |
| Cash flow from Operations | 7,335 | 3,000 | 3,648 | 1,897 |
| Cash flow from Investing | -3,865 | -4,172 | -1,712 | -1,287 |
| Cash flow from Financing | -846 | 1,732 | -2,184 | -337 |
| Total Cash Flow | 2,624 | 560 | -248 | 273 |
| Cash (Start of the year) | 1,544 | 984 | 1,232 | 991 |
| Cash (End of the year) | 4,168 | 1,544 | 984 | 1,265 |
Figures in ₹ crore unless the line item is per-share.
09/Events
Corporate actions
Dividends, bonuses, splits and rights issues. Filter by type, sort by any date, and expand a row for the full event detail.
| DividendFinal | ₹18.00 | 900.0% | 17 Jul 2026 | 17 Jul 2026 | 07 May 2026 |
10/Comparison
Peers & competitors
Competitor set priced live. Filter by sector, sort any column, and expand a peer for its business description.
| SUNPHARMASUN Pharmaceutical IND L | Pharmaceuticals | ₹1,884.90 | -0.79% | 19.16 L | ₹4,52,299 Cr | $50.26B | |
| DIVISLABDivi S Laboratories Ltd | Pharmaceuticals | ₹11,180.50 | +0.02% | 4.05 L | ₹2,97,325 Cr | $33.04B | |
| TORNTPHARMTorrent Pharmaceuticals L | Pharmaceuticals | ₹4,689.50 | +1.70% | 2.00 L | ₹1,78,727 Cr | $19.86B | |
| LAURUSLABSLaurus Labs Limited | Pharmaceuticals | ₹2,294.60 | -0.49% | 8.79 L | ₹1,24,002 Cr | $13.78B | |
| ZYDUSLIFEZydus Lifesciences Ltd | Pharmaceuticals | ₹1,200.00 | -0.24% | 7.80 L | ₹1,19,207 Cr | $13.25B | |
| DRREDDYDR. Reddy S Laboratories | Pharmaceuticals | ₹1,390.20 | -0.76% | 8.31 L | ₹1,16,145 Cr | $12.90B | |
| CIPLACipla Ltd | Pharmaceuticals | ₹1,415.00 | -0.25% | 14.84 L | ₹1,14,312 Cr | $12.70B | |
| MANKINDMankind Pharma Limited | Pharmaceuticals | ₹2,665.00 | +1.37% | 4.56 L | ₹1,09,870 Cr | $12.21B | |
| AUROPHARMAAurobindo Pharma Ltd | Pharmaceuticals | ₹1,799.00 | -0.37% | 8.11 L | ₹1,03,298 Cr | $11.48B | |
| GLENMARKGlenmark Pharmaceuticals | Pharmaceuticals | ₹2,648.00 | +1.51% | 5.40 L | ₹74,733 Cr | $8.30B |
Market cap is the sector-constituent figure reported per peer · Showing 1–10 of 10
11/Coverage
Company news
Articles published in the last seven days, paginated by the provider.
No news in the last seven days
Company news is available for a rolling one-week window.